Benefit from autologous stem cell transplantation in primary refractory myeloma? Different outcomes in progressive versus stable disease.

Autores de IIS La Fe

• 

  Javier De La Rubia Comos

  Autor

Participantes ajenos a IIS La Fe

• Rosiñol L
• García-Sanz R
• Lahuerta JJ
• Hernández-García M
• Granell M
• Oriol A
• Hernández-Ruiz B
• Rayón C
• Navarro I
• García-Ruiz JC
• Besalduch J
• Gardella S
• López Jiménez J
• Díaz-Mediavilla J
• Alegre A
• San Miguel J
• Bladé J
• PETHEMA/Spanish Myeloma Group

Grupos

• Hematología y Hemoterapia

  

  Investigador Principal

  Javier De La Rubia Comos

Abstract

Several studies of autologous stem cell transplantation in primary refractory myeloma have produced encouraging results. However, the outcome of primary refractory patients with stable disease has not been analyzed separately from the outcome of patients with progressive disease.